

## Chief Commercial Officer Appointment

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

### Key Highlights:

- Experienced pharmaceutical sector executive, Mr Robert Clements, appointed to newly created role of Chief Commercial Officer.
- Recently appointed London based Chief Financial Officer commences employment.
- Restructure of key executive roles, and establishment of UK based corporate team now complete.

**MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’)**, a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the appointment of experienced pharmaceutical industry executive Mr Robert Clements to the newly created position of Chief Commercial Officer.

The Chief Commercial Officer role brings together oversight and leadership of all MGC Pharma’s key commercial functions including Business Development, Marketing and Sales. Mr Clements brings with him over 30 years of international experience in the pharmaceuticals sector, having previously held several senior roles in business development, commercial and marketing. Most recently, Mr Clements was Vice President Business Development of the international rare medicines division of Sciensus Rare, an international pharmaceutical services company based in the Netherlands, specialising in the provision of rare disease medicines. An expert in market development for rare and chronic diseases, Mr Clements’ appointment will help drive forward the Company’s strategy and goal of becoming a leading supplier of plant derived medicines.

**MGC Pharma’s newly appointed Chief Commercial Officer, Rob Clements commented,** “I am excited to join MGC Pharma at this crucial time for the business. The Pharmaceutical industry relies on constant innovation and the Company has proven itself to be creative and innovative in its approach to treating serious disease and meeting patient needs for products that work effectively.”

#### *Commencement of now London based CFO*

Additionally, the Company advises that Ms. Angela Marie Graham has commenced in her role as MGC Pharma’s new London based Chief Financial Officer, which along with Mr Clements appointment completes the restructure of the Company’s Executive Team. Ms Graham has over 25 years of accountancy experience, specialising in growth businesses in emerging industries, including those within the biopharmaceutical sector.

**Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals,** commented “We are pleased to have Rob join the MGC Pharma team, and look forward to working with him closely in this new role. His appointment follows that of Angela-Marie as our new London based Chief Financial Officer, and completes the restructure of MGC Pharma Executive team.”

--Ends--

**Authorised for release by the Executive Chairman, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Broker – Turner Pope**

Andy Thacker  
+44 203 657 0050  
[info@turnerpope.com](mailto:info@turnerpope.com)

**MGC Pharmaceuticals Ltd**

David Lim  
Company Secretary  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK PR Advisors – Tavistock**

Charles Vivian / Tim Pearson  
+44 207 920 3150  
[mgcpharma@tavistock.co.uk](mailto:mgcpharma@tavistock.co.uk)

## About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels

